Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | HCK | P08631 | 18/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 17/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 0.81 |
| ▸ | SYK | P43405 | 1/20 | 0.81 |
| ▸ | GSK3B | P49841 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jnj-49095397 SCHEMBL29893666 | 1.00 | MAPK14 (1.00) | MAPK14HCKMAPK12SRCGSK3A | |
| Jnj-49095397 SCHEMBL29443619 | 1.00 | MAPK14 (1.00) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL12540862 | 0.94 | MAPK14 (0.89) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL12540015 | 0.93 | MAPK14 (0.87) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL2406556 | 0.93 | MAPK14 (1.00) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL12541238 | 0.93 | MAPK14 (0.86) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL13563468 | 0.93 | MAPK14 (0.86) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL14656497 | 0.92 | MAPK14 (0.86) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL18546374 | 0.92 | MAPK14 (0.85) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL2405784 | 0.92 | MAPK14 (0.85) | MAPK14HCKMAPK12SRCGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| EP-3478322-B1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | HVIVO SERVICES LTD (GB) | 2020-12-30 | — | — | EP | claimed |
| EP-2509595-B1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD (GB) | 2018-04-11 | — | — | EP | claimed |
| EP-2370428-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-08-10 | — | — | EP | claimed |
| EP-2582432-B1 | UREIDO-PYRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS | RESPIVERT LTD (GB) | 2014-11-19 | — | — | EP | claimed |
| US-20140114064-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2014-04-24 | — | — | US | claimed |
| EP-2350049-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-02-26 | — | — | EP | claimed |
| US-20130102607-A1 | UREIDO-PYRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS | RESPIVERT LIMITED (US) | 2013-04-25 | — | — | US | claimed |
| US-8293748-B2 | p38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-23 | — | — | US | claimed |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-09-01 | — | — | US | claimed |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | POOLBEG PHARMA UK LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-4396191-B1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2026-02-18 | — | — | EP | disclosed |
| US-12350302-B2 | Dosing regime and formulations for type B adenoviruses | Akamis Bio Limited (GB) | 2025-07-08 | — | — | US | disclosed |
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2025-02-11 | — | — | US | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| US-20110269800-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110269800-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-09-01 | — | — | US | disclosed |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885HCK 546/4885MAPK12 12/4885 |
| US-20110269800-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K11, MAP3K1 | MAPK14 22/4885HCK 733/4885MAPK12 23/4885 |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | MAPK14 10/4885HCK 348/4885MAPK12 13/4885 |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK6 | MAPK14 33/4885HCK 2830/4885MAPK12 31/4885 |
| US-20140114064-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK6 | MAPK14 33/4885HCK 2830/4885MAPK12 31/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | MAPK14 14/4885HCK 546/4885MAPK12 12/4885 |
| US-20130102607-A1 | UREIDO-PYRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS | URB2, RPL35, PRPF3 | MAPK14 3791/4885HCK 4717/4885MAPK12 3947/4885 |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | MAPK13, MAPK11, MAPK1 | MAPK14 18/4885HCK 252/4885MAPK12 5/4885 |
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | AHR, ARNT, NQO1 | MAPK14 2848/4885HCK 1845/4885MAPK12 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.